Debate Over Addyi Flares Anew

March 2016 -- A review of eight clinical trials testing flibanserin (Addyi), the first and only drug on the market to treat hypoactive sexual desire disorder (HSDD) in women, concluded the drug performed on the low end of the clinical efficacy range used to gain FDA approval. However, women's health experts argue that the drug earned its approval and should remain in the treatment arsenal.

Read More


Share this article